Investigation of biofilm production and its association with genetic and phenotypic characteristics of OM (osteomyelitis) and non-OM orthopedic Staphylococcus aureus

Table 4 Relationship between biofilm production and drug resistance

Strain trait	Total (n = 137)	OM (n = 60)	Non-OM (n = 77)
Strain trait	N (%), P value^a
MRSA	30 (21.9), 0.038 (rho =−0.169, P = 0.048)^b	9 (15.0), 0.553	21 (27.3), 0.042 (rho = −0.238, P = 0.037)^b
MDR	40 (29.2), 0.089	18 (30.0), 0.113	22 (28.6), 0.387
CIP-resistant	12 (8.8), 0.533	6 (10.0), 0.641	6 (7.8), 0.191
CLI-resistant	62 (45.3), 0.151	27 (45.0), 0.202	35 (45.5), 0.417
ERY-resistant	67 (48.9), 0.245	27 (45.0), 0.390	40 (51.9), 0.454
GEN-resistant	12 (8.8), 0.455	6 (10.0), 0.711	6 (7.8), 0.133
LVX-resistant	10 (7.3), 0.260	4 (6.7), 0.598	6 (7.8), 0.368
MFX-resistant	9 (6.6), 0.528	4 (6.7), 0.876	5 (6.5), 0.416
OXA-resistant	32 (23.4), 0.456	13 (21.7), 0.395	19 (24.7), 0.776
PEN-resistant	125 (91.2), 0.888	53 (88.3), 0.340	72 (93.5), 0.367
RIF-resistant	7 (5.1), 0.121	5 (8.3), 0.256	2 (2.6), 0.836
SXT-resistant	13 (9.5), 0.946	4 (6.7), 0.109	9 (11.7), 0.318
TCY-resistant	38 (27.7), 0.031 (rho = −0.185, P = 0.031)^b	21 (35.0), 0.098	17 (22.1), 0.133

All the strains were susceptible to LNZ, TGC and VAN. Significant differences are in italics
^aBy Mann–Whitney U test, comparing biofilm production (OD₄₉₂ values) between resistant and non-resistant strains in each group
^bSignificant factors were further subjected to spearman correlation analyses

ISSN: 1476-0711